Mortality surrogates in combined pulmonary fibrosis and emphysema

An Zhao - an.zhao.19@ucl.ac.uk1

Dr Eyjolfur Gudmundsson - e.gudmundsson@ucl.ac.uk1

Prof Nesrin Mogulkoc - nesrin.mogulkoc@gmail.com²

Dr Coline van Moorsel - c.van.moorsel@antoniusziekenhuis.nl³

Prof Tamera J. Corte – tameracorte@mac.com⁴

Dr Chiara Romei - chiara.romei@gmail.com⁵

Dr Robert Chapman - robert.chapman2@nhs.net⁶

Dr Tim J.M. Wallis - timothy.wallis@soton.ac.uk⁷

Dr Emma Denneny - e.denneny@ucl.ac.uk6

Dr Tinne Goos - tinne.goos@kuleuven.be^{8,9}

Dr Recep Savas - recepsavas@gmail.com¹⁰

Dr Asia Ahmed - asia.ahmed1@nhs.net11

Dr Christopher J. Brereton - c.j.brereton@soton.ac.uk⁷

Dr Hendrik W. van Es - h.es@antoniusziekenhuis.nl³

Dr Helen Jo - Helen.Jo@health.nsw.gov.au⁴

Dr Annalisa De Liperi – a.deliperi@ao-pisa.toscana.it⁵

Dr Mark Duncan - markduncan2@nhs.net11

Dr Katarina Pontoppidan - katarinapontoppidan@gmail.com⁷

Dr Laurens J. De Sadeleer - laurens.desadeleer@kuleuven.be^{9,12}

Dr Frouke van Beek - f.van.beek@antoniusziekenhuis.nl³

Dr Joseph Barnett – josephbarnett@nhs.net¹³

Dr Gary Cross - gary.cross@nhs.net14

Dr Alex Procter - alex.procter@nhs.net11

Dr Marcel Veltkamp - m.veltkamp@antoniusziekenhuis.nl^{3,15}

Prof Peter Hopkins - peter hopkins@health.qld.gov.au¹⁶

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Prof Yuben Moodley - yuben.moodley@uwa.edu.au^{17,18}

Dr Alessandro Taliani – alessandrotaliani89@gmail.com⁵

Dr Magali Taylor - magali.taylor@nhs.net¹¹

Dr Stijn Verleden - stijn.verleden@uantwerpen.be¹⁹

Dr Laura Tavanti - 1.tavanti@ao-pisa.toscana.it²⁰

Dr Marie Vermant - marie.vermant@kuleuven.be^{8,9}

Dr Arjun Nair - Arjun.nair1@nhs.net¹¹

Dr Iain Stewart - iain.stewart@imperial.ac.uk²¹

Prof Sam M. Janes - s.janes@ucl.ac.uk²²

Dr Alexandra L. Young - alexandra.young@kcl.ac.uk^{1,23}

Prof David Barber - david.barber@ucl.ac.uk²⁴

Prof Daniel C. Alexander - d.alexander@ucl.ac.uk1

Prof Joanna C. Porter - joanna.porter@ucl.ac.uk⁶

Prof Athol U. Wells - RBHILD@rbht.nhs.uk^{25,26}

Dr Mark G. Jones - mark.jones@soton.ac.uk⁷

Prof Wim A. Wuyts - wim.wuyts@uzleuven.be^{8,9}

Dr Joseph Jacob - j.jacob@ucl.ac.uk^{1,22}

College London Hospitals NHS Foundation Trust, London, UK

⁷NIHR Southampton Biomedical Research Centre and Clinical and Experimental

Sciences, University of Southampton, Southampton, UK

¹Centre for Medical Image Computing, UCL, London, UK

²Department of Respiratory Medicine, Ege University Hospital, Izmir, Turkey

³Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, Netherlands

⁴Department of Respiratory Medicine, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia

⁵Department of Radiology, Pisa University Hospital, Pisa, Italy

⁶Interstitial Lung Disease Service, Department of Respiratory Medicine, University

⁸BREATHE, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium

⁹Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium

¹⁰Department of Radiology, Ege University Hospital, Izmir, Turkey

¹¹Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK

¹²Institute of Lung Health and Immunity (LHI) / Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München, Munich, Germany

¹³Department of Radiology, Royal Free London NHS Foundation Trust, London, UK

¹⁴Department of Radiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK

¹⁵Division of Heart and Lungs, University Medical Center, Utrecht, Netherlands

¹⁶Queensland Centre for Pulmonary Transplantation and Vascular Disease, The Prince Charles Hospital, QLD, Australia

¹⁷School of Medicine & Pharmacology, University Western Australia, WA, Australia ¹⁸Fiona Stanley Hospital, Perth, Australia

¹⁹Antwerp Surgical Training, Anatomy and Research Centre (ASTARC), Faculty of Medicine and Health Sciences, University of Antwerp, Edegem, Belgium

²⁰Cardiovascular and Thoracic Department, Pisa University Hospital, Pisa, Italy

²¹National Heart and Lung Institute, Imperial College London, London, UK

²²Lungs for Living Research Centre, UCL, London, UK

²³Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

²⁴Centre for Artificial Intelligence, UCL, London, UK

²⁵Department of Respiratory Medicine, Royal Brompton Hospital, London, UK

²⁶Imperial College London, London, UK

Corresponding author: Dr Joseph Jacob

UCL Centre for Medical Image Computing

1st Floor, 90 High Holborn, London WC1V6LJ j.jacob@ucl.ac.uk **Abstract**

Background: Idiopathic pulmonary fibrosis (IPF) with co-existent emphysema,

termed combined pulmonary fibrosis and emphysema (CPFE) may be associated with

reduced FVC decline compared to non-CPFE IPF patients. We examined associations

between mortality and functional measures of disease progression in two IPF cohorts.

Methods: Visual emphysema extent (CPFE:non-CPFE: derivation cohort=317:183;

replication cohort=358:152), scored on computed tomography imaging subgrouped

CPFE patients using either a) 10%, or b) 15% visual emphysema threshold, or c) an

unsupervised machine learning model considering emphysema and ILD extents.

Baseline characteristics, 1-year forced vital capacity (FVC) and diffusion capacity for

carbon monoxide (DLco) decline (linear mixed effects models), and their associations

with mortality (multivariable Cox regression models) were compared across CPFE

and non-CPFE subgroups.

Results: In both IPF cohorts, CPFE patients with >10% emphysema had a greater

smoking history and lower baseline DLco compared to CPFE patients with <10%

emphysema. Using multivariable Cox regression analyses in patients with >10%

emphysema, 1-year DLco decline was a better indicator of mortality than 1-year FVC

decline. Results were maintained in patients suitable for therapeutic IPF trials.

Results were replicated in the >15% emphysema population and using unsupervised

machine learning. Importantly, the unsupervised machine learning approach identified

CPFE patients in whom FVC decline did not associate strongly with mortality. In non-

CPFE IPF patients, 1-year FVC declines >5% and >10% showed comparable

mortality associations.

Conclusion: When assessing disease progression in IPF, DLco decline should be

considered in patients with >10% emphysema and a >5% 1-year FVC decline

threshold considered in non-CPFE IPF patients.

KEYWORDS: Combined pulmonary fibrosis and emphysema, mortality surrogates,

idiopathic pulmonary fibrosis, computed tomography.

Introduction

Emphysema is a common pulmonary finding on computed tomography (CT) imaging of idiopathic pulmonary fibrosis (IPF) patients [1]. The term combined pulmonary fibrosis and emphysema (CPFE) describes a potential clinical endotype characterized by the coexistence of upper lobe-predominant emphysema, lower lobe-predominant fibrosis and relative preservation of forced vital capacity (FVC) in the context of a disproportionately reduced gas transfer (DLco) [1–3]. CPFE is highly heterogeneous in terms of the distribution and relative extents of fibrosis and emphysema seen on CT.

CPFE patients are typically categorised using visual thresholds of emphysema extent: >0%, >5%, >10%, >15%. It has been suggested that a subset of CPFE patients (>15% emphysema) may manifest slower rates of FVC decline than CPFE patients with lesser amounts of emphysema [4]. Despite the importance of fibrosis in driving FVC decline, fibrosis extent hasn't been considered in prior definitions of CPFE [5]. Categorisation of CPFE patients using a combination of fibrosis and emphysema is possible using data-driven machine learning methods. SuStaIn [6] is a machine learning method initially proposed for subtyping and modelling disease progression behaviour in dementia, which has been extended to COPD [7]. SuStaIn can identify disease subtypes with different progression patterns and can reconstruct their progression trajectories from cross-sectional data. A by-product of this approach would be the identification of patients in different CPFE subtypes who may benefit

from different forms of disease progression monitoring, which in turn could inform

clinical trial design.

In our study, we therefore aimed to assess whether FVC decline, the most widely used

surrogate for mortality prediction in IPF associated with mortality in independent

CPFE populations with >10% and >15% emphysema scored visually on CT imaging,

and in CPFE subgroups categorised by considering relative extents of interstitial lung

disease (ILD) and emphysema. We further examined whether DLco decline could

8

represent an alternative surrogate for mortality in IPF patients with CPFE [5, 8].

Methods

Cohorts

Two independent IPF cohorts diagnosed by multidisciplinary teams were studied. The derivation cohort (n=500) derived from three centres: Ege University Hospital, Izmir, Turkey; St Antonius Hospital, Nieuwegein, Netherlands; Pisa University Hospital, Italy. The replication cohort (n=510) derived from four centres: University Hospital Southampton NHS Foundation Trust, UK; University College London Hospitals NHS Foundation Trust, UK; University Hospitals Leuven, Belgium; Australian IPF registry, Australia. Approval for this retrospective study of clinically indicated pulmonary function and CT data were obtained from the local research ethics committees and Leeds East Research Ethics Committee: 20/YH/0120.

Visual CT Scoring of Emphysema and ILD

Patients with infection or cancer on baseline CT or who died within 3 months of the baseline CT were excluded from the study. Emphysema extent and fibrosis extent were visually scored in 6 lobes (the lingula was counted as the sixth lobe) by an experienced radiologist (JJ). Fibrosis extent comprised the sum of ground glass density (with overlying reticulation or traction bronchiectasis), reticulation, traction bronchiectasis and honeycomb cysts. Lobar extents of emphysema/fibrosis were summed and divided by 6 to obtain a lung percentage of emphysema/fibrosis. CPFE

patients were subdivided in a primary analysis into those >10% emphysema (Figure 1), and in a secondary analysis into those >15% emphysema. A subset of 122 cases were evaluated independently by two radiologists (GC and JB: 3 and 4 years imaging experience respectively) to provide an estimate of observer variation in CT scores.

FVC/DLco Decline Modelling

Linear mixed-effects (LME) models estimated absolute and relative 1-year FVC decline and 1-year DLco decline. The trajectory of FVC for patients from different countries/centres was modelled separately by using the LME model. Fixed effects included: age at baseline CT date, gender, smoking history (never vs. ever), antifibrotics (never vs. ever), baseline percent predicted FVC (nearest to and within 3 months of baseline CT date), and time since baseline CT imaging date. Each subject had a random intercept and random slope. FVC measurements between baseline FVC date and 18 months after baseline CT date were used to build the LME model. Patients required at least two FVC measurements during this period and an FVC measurement within 3 months of baseline CT for study inclusion. Absolute and relative 1-year FVC declines were calculated. For relative 1-year FVC decline, each follow-up FVC measurement (mls) was divided by baseline FVC (mls) and multiplied by 100 [9] and LME-predicted relative FVC percentage calculated at 1 year. 1-year DLco decline was estimated using similar methods, with longitudinal DLco and baseline percent predicted DLco used in the LME models. LME models were implemented with MATLAB (version R2019b, Mathworks, Natick, Massachusetts,

US).

Machine learning delineation of CPFE subtypes

Only patients with emphysema scored visually in any lobe were considered for SuStaIn CPFE analysis. Using baseline data alone, SuStaIn can identify disease subtypes with distinct progression trajectories that describe the z-score evolution of multiple biomarkers. Z-scores for fibrosis and emphysema were calculated separately and were based on the interobserver variability (measured using the single determination standard deviation) between two radiologists visually estimating fibrosis and emphysema extent. For an individual CPFE subtype, fibrosis and emphysema within each of the six lobes was modelled as a monotonically increasing piece-wise linear function [6, 7]. The trained SuStaIn model, by reconstructing disease progression trajectories of each subtype, can predict probabilities that an individual belongs to a particular subtype and stage [6].

Statistical analysis

Data are presented as means and standard deviations unless otherwise stated. Two-sample t-tests were used for continuous variables, and chi-squared tests were used for categorical variables. Kaplan-Meier survival plots and the log-rank test were used to test for differences in survival between non-CPFE IPF patients, and CPFE patients in different subgroups (using emphysema thresholds or SuStaIn subtype) in both IPF

cohorts. Subanalyses were performed for patients satisfying lung function criterion for inclusion into IPF therapeutic trials (percent predicted DLco >30%, percent predicted FVC >50%, and forced expiratory volume in the first second/FVC ratio >0.7).

In multivariable mixed-effects Cox regression models associations of FVC decline and DLco decline with mortality were examined across IPF subtypes. Models were adjusted for age, gender, smoking history (never vs. ever), antifibrotic use (never vs. ever), and baseline disease severity (using percent predicted DLco at baseline). Differences between different countries/centres in each cohort were modelled by assigning a random intercept for each centre. Cox models were used with a minimum of 8 outcome events per predictor covariant [10]. The Concordance index (C-index) compared the goodness of fit of Cox regression models. P-values <0.01 were considered statistically significant. All mixed-effects Cox regression analyses were implemented by R (version 4.0.3 with Rstudio version 1.3.1093, Rstudio, Boston, Massachusetts, US).

To investigate the impact of emphysema on FVC and DLco decline in the different IPF subgroups (non-CPFE patients; CPFE patients classified using emphysema thresholds or SuStaIn), proportions of patients with >5% and >10% relative FVC decline in 1-year and >10% and >15% relative DLco decline in 1-year were calculated. Mean absolute 1-year FVC decline (mls) and DLco decline (mls) was also calculated for the three subgroups. Analyses were performed in both IPF cohorts, with

subanalyses in subjects fulfilling criteria for inclusion into IPF therapeutic trials. Chi-squared tests with Bonferroni-adjusted p-values were calculated for categorical variables. A one-way ANOVA test examined differences in mean absolute FVC decline (ml/year) with a post hoc Tukey Honest Significant Difference (HSD) test used to compare pairwise differences in subtypes.

Results

Baseline characteristics

317/500 (63%) IPF patients in the derivation cohort had emphysema and were defined

as CPFE compared to 358/510 (70%) IPF patients with CPFE in the replication cohort.

CPFE patients were more likely to be smokers, had a higher percent-predicted FVC

and lower percent-predicted DLco than non-CPFE patients.

Across the derivation and replication cohorts, CPFE patients with >10% emphysema

comprised greater numbers of smokers and had lower baseline percent predicted

DLco compared to CPFE patients with <10% emphysema (Table 1). To power

analyses, patients in both IPF cohorts fulfilling entry criteria for therapeutic trials

were combined into a single cohort (Supplementary Table 1). Baseline characteristics

of CPFE patients with emphysema above or below 15% in derivation and replication

cohorts are shown in Supplementary Tables 2-3.

The interobserver variation in visual emphysema scores, measured using Cohens

Kappa for 0%, 5%, 10%, and 15% emphysema thresholds was: 0.2, 0.5, 0.61, 0.69,

respectively demonstrating substantial agreement for a 10% visual emphysema

14

threshold.

Machine Learning Model

Machine learning analyses of ILD and emphysema extents in the CPFE population

identified two distinct CPFE subtypes. One subtype (Fibrosis Dominant CPFE; 60%

of derivation cohort CPFE patients and 61% of replication cohort CPFE patients) had

much more extensive fibrosis at an early stage followed by a later emergence of

emphysema (Supplementary Figure 3 and 4). The second subtype (Matched CPFE)

demonstrated fibrosis and emphysema worsening together, with later stages showing

relatively more extensive emphysema and less fibrosis compared to the fibrosis-

dominant CPFE subtype (Supplementary Table 4 and 5).

PFT decline analyses

Fewer CPFE patients with >10% emphysema reached the >10% or >5% 1-year FVC

decline thresholds and had lower mean absolute FVC declines, though differences

between groups did not reach statistical significance (Table 2). Greater numbers of

CPFE patients with >10% emphysema demonstrated 1-year DLco declines >15%,

though again results did not reach statistical significance (Table 3). Similar trends

were found in the replication cohort, patients fulfilling criteria to enter IPF therapeutic

trials (Table 2 and 3), and when CPFE was categorized using a 15% emphysema

15

threshold or machine learning analyses (Supplementary Table 6 and 7).

Survival Analyses

Kaplan-Meier survival plots (Figure 2) demonstrated that in both cohorts, non-CPFE

and CPFE patients with <10% emphysema had a significantly better prognosis than

CPFE patients with >10% emphysema. Results were maintained in patients fulfilling

criteria to enter IPF therapeutic trials and were similar when CPFE patients were

separated using a 15% emphysema threshold or machine learning analyses

(Supplementary Figure 1 and 2).

Mortality analysis for visual emphysema thresholds

Multivariable Cox regression models adjusted for patient age, gender, smoking

history (never vs. ever), antifibrotic use (never vs. ever), and baseline percent

predicted DLco showed that across both study cohorts, in non-CPFE patients, a 5% 1-

year FVC decline threshold showed equivalent associations with mortality as

compared to a 10% 1-year FVC decline threshold (Tables 4 and 5). A 5% 1-year FVC

decline threshold identified more non-CPFE patients (derivation cohort=59%;

replication cohort=108%) than a 10% 1-year FVC decline threshold (Table 2).

Associations with mortality were maintained in patients fulfilling criteria to enter IPF

therapeutic trials (Supplementary Table 8), where 78% more non-CPFE patients

had >5% 1-year FVC declines compared to patients with >10% 1-year FVC decline

(Table 2).

For CPFE patients with >10% emphysema (derivation cohort n=103/352 (29%);

16

replication cohort n=115/382 (30%)), 1-year DLco decline showed a much stronger association with mortality than 1-year FVC decline in derivation and replication cohorts (Table 4 and 5). 1-year FVC decline did not associate significantly with mortality in the replication cohort (Table 5). When DLco thresholds were examined in CPFE patients with >10% emphysema in both cohorts, >15% 1-year DLco decline showed stronger associations with mortality than >10% 1-year FVC decline. In subjects eligible for inclusion into IPF therapeutic trials (where 144/589 (24%) patients had >10% emphysema) DLco decline showed stronger associations with mortality than FVC decline (Supplementary Table 8). Similar trends were observed in multivariable analyses performed in CPFE patients with >15% emphysema (Supplementary Table 9-11).

Mortality analyses of machine learning derived CPFE subgroups

Trends seen for the 10% visual emphysema threshold were again replicated when CPFE patients were separated using machine learning analyses that considered ILD and emphysema extents. The *Matched CPFE* cohort better delineated patients in whom FVC decline proved a poor surrogate for mortality compared to visual emphysema thresholds of >10% and >15%. Importantly, in the *Matched CPFE* cohort, DLco decline, whether measured as absolute decline or a >15% DLco threshold remained a strong surrogate for mortality (Supplementary Table 12-14).

17

Discussion

Our study evaluated functional indicators of disease progression in IPF patients with emphysema that have been the key mortality surrogates used in clinical care and therapeutic trials. We identified three important findings across two IPF populations: Firstly, we demonstrated the limited associations between FVC decline and mortality in CPFE patients with >10% and >15% emphysema, and conversely the strong associations with mortality for DLco decline in the same subgroups. Second, our machine learning model identified a subgroup of CPFE patients where a relatively greater amount of emphysema compared to ILD accentuated the limited associations between ILD-driven FVC decline and mortality in these CPFE patients. Lastly, in non-CPFE patients we showed that FVC decline is a powerful measure of IPF progression showing comparable associations with mortality for both >5% and >10% 1-year FVC decline thresholds. Using a >5% 1-year FVC decline threshold in non-CPFE patients identified over 50% more subjects with real declines than when using a >10% 1-year FVC decline threshold.

FVC decline occupies a cardinal role in the assessment of disease progression in IPF as it has been shown to be a strong surrogate for mortality [11]. The demonstration however that FVC decline may be curtailed in IPF patients with >15% [4] emphysema raised the question of whether FVC decline remained a surrogate for mortality in IPF patients with more extensive emphysema. Only one other study, by

Schmidt et al [8], which was relatively underpowered (n=42) for subjects with

moderate/severe emphysema (defined as emphysema at least as extensive as ILD),

addressed this question and found that FVC decline did not associate with mortality at

12 months. Other studies considering IPF patients regardless of emphysema

presence/extent have shown strong associations between mortality and other

functional decline measures/thresholds including: DLco decline thresholds of >10%

[12] and 15% [13], and FVC declines of >5% [14–16].

An explanation for the poor association between FVC decline and mortality in

patients with more extensive emphysema may relate to the impact of fibrosis when

encroaching on areas of emphysema. Emphysematous regions of lung commonly

demonstrate air trapping as thickened small airways collapse on expiration. Fibrotic

processes however can irreversibly pull open small airways. The supervening traction

bronchiolectasis can result in emphysematous airspaces being ventilated, thereby

artificially preserving FVC. In IPF patients with emphysema, as fibrosis progresses

and extends to involve the upper zones of the lungs, more emphysematous lung may

become incorporated into the expiratory lung volume over time. A consequence may

more heterogeneity in expiratory volumes superimposing considerable noise to the

overarching pattern of progressive FVC decline. This effect is likely to be more

pronounced in patients with more extensive emphysema.

One limitation in prior definitions of CPFE has been the focus on emphysema extent 19

ATS/ERS/ALAT/JRS research statement identified a 5% emphysema threshold as a research definition for CPFE patients, whilst suggesting a 15% emphysema threshold for classifying a CPFE clinical syndrome [5]. In our study we found that a 10%

alone as the sole arbiter for categorising a CPFE endotype. A recent

emphysema threshold (which showed substantial CT observer agreement) may

represent a better cut-off than a 15% emphysema threshold to identify a CPFE

population disenfranchised by the use of FVC as a sole measure of disease

progression.

A further challenge with CPFE definitions being determined by emphysema

thresholds is that FVC decline is primarily driven by ILD progression rather than

emphysema progression. Our novel unsupervised machine learning model (SuStaIn)

considered both fibrosis and emphysema when subtyping patients and replicated the

strong association of DLco decline and mortality in patients with more extensive

emphysema seen in CPFE patients with >10% emphysema. By considering ILD

extent in relation to emphysema extent, the SuStaIn model improved delineation of a

subgroup of CPFE patients, fulfilling criteria to enter IPF therapeutic trials, where

FVC decline did not associate strongly with mortality. This could have implications

for assessing disease progression in future IPF clinical trials.

Prior studies have shown associations between DLco decline and mortality in IPF [8,

12, 13, 17–19] but have not analysed the impact of emphysema on DLco trends. DLco

decline has generally been less consistent in its links with mortality than FVC decline in IPF patients [20]. Yet DLco decline may have particular relevance in subsets of IPF patients [21]. For example, the strong mortality signal for DLco decline seen in CPFE patients with more extensive emphysema could reflect progressive localised pulmonary hypertension complicating CPFE patients with more extensive emphysema [22, 23].

There were limitations to the current study. A single observer scored the CTs for fibrosis and emphysema. For studies to be clinically meaningful, they have to be suitably powered, and this requires the careful evaluation of large IPF populations which is challenging with limited availability of radiologists. The single read of CTs in this study aligns with other large scale IPF studies where pragmatic considerations required assessment of CTs by a single specialist [24, 25]. Similar functional measures and IPF subgroups proportions across both study cohorts provides reassurance for the validity of the visual CT scores. The improvement in observer agreement at higher emphysema thresholds (even amongst less experienced radiologists) adds confidence to the reliability of visual scores at an emphysema threshold of 10%. This also aligns with prior work [26] demonstrating improved interobserver agreement at emphysema extent categories of 10% and 15% versus 0% and 5%. Lastly, whilst we would have liked to have fully automated our machine learning model, using computationally quantified emphysema as an objective measure of disease, no existing automated tools can reliably distinguish emphysema from honeycombing and traction bronchiectasis. Accordingly, there will remain a reliance

on visual CT reads for assessing the emphysematous component of CPFE in the near

future.

In conclusion, annual DLco decline was shown to be a better mortality surrogate for

patients with more than 10% emphysema than FVC decline. Findings were validated

by a data-driven machine learning method that considers emphysema and ILD extents

when defining patients with more extensive emphysema. These observations may be

useful in clinical trial design to identify subjects where FVC decline is a poor disease

progression measure. A 5% 1-year FVC decline threshold however was found to be a

comparable mortality indicator to a 1-year 10% FVC decline threshold in non-CPFE

22

IPF patients.

Acknowledgments

This research was funded in whole or in part by the Wellcome Trust [209553/Z/17/Z]. For the purpose of open access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission. This project, JJ, EG, ED, SMJ and JCP were also supported by the NIHR UCLH Biomedical Research Centre, UK. MGJ, TJMW and CJB acknowledge the support of the NIHR Southampton Biomedical Research Centre. AZ was supported by CSC-UCL Joint Research Scholarship. The Australian IPF Registry is an initiative of Lung Foundation Australia and is supported by Foundation partners Boehringer Ingelheim, Roche Products Pty. Limited.

Disclosure of Conflicts of Interest

JJ reports fees from Boehringer Ingelheim, Roche, NHSX, Takeda and GlaxoSmithKline unrelated to the submitted work. JJ was supported by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z and the NIHR Biomedical Research Centre at University College London. NM reports grant TUBITAK (EJP Rare Disease project "COCOS-IPF"), fees from Boehringer, Ingelheim, Roche, and Nobel Turkey unrelated to the submitted work. NM received support for travel to ATS 2020 and ATS 2021 from Roche, and to ERS 2020 from Actelion. TG is supported by Research Foundation–Flanders (FWO)-1S73921N.

LJDS is supported by Marie Sklodowska-Curie actions postdoctoral fellowship within the European Union's Horizon Europe research and innovation programme. HJ reports fees from Boehringer ingelheim and Roche. HJ received assistance for travel to meetings from Boehringer ingelheim and Roche. SV reports consultancy fees from Boehringer-Ingelheim and Sanofi. MV is supported by FWO (Research Flanders Foundation) Fellowship. SMJ reports fees from Astra-Zeneca, Bard1 Bioscience, Achilles Therapeutics, and Jansen unrelated to the submitted work. SMJ received assistance for travel to meetings from Astra Zeneca to American Thoracic Conference 2018 and from Takeda to World Conference Lung Cancer 2019 and is the Investigator Lead on grants from GRAIL Inc, GlaxoSmithKline plc and Owlstone. AUW reports personal fees and non-financial support from Boehringer Ingelheim, Bayer and Roche Pharmaceuticals; and personal fees from Blade, outside of the submitted work. AZ, EG, CvM, RC, TJMW, ED, RS, AA, CJB, HWvE, MD, KP, FvB, GC, AP, MV, YM, MT, AN, IS, ALY, DB, DCA, JCP, MGJ, RS, WAW report no relevant conflicts of interest.

Author Contributions

AZ, EG, IS, ALY, DB, DCA, AUW, and JJ contributed to study design and data interpretation. AZ, EG, NM, MGJ, CvM, TJC, CR, RC, TJMW, ED, TG, RS, AA, CJB, HWvE, HJ, ADL, MD, KP, LJDS, FvB, JB, GC, AP, MV, PH, YM, AT, MT, SV, LT, MV, AN, SMJ, JCP, MGJ, WAW and JJ were responsible for data acquisition. AZ, EG, IS, and JJ contributed to the statistical analysis. AZ and JJ prepared the first draft of the manuscript. AZ and JJ were responsible for study data integrity. All authors reviewed the manuscript and approved the final submitted version.

Table 1. Baseline characteristics of non-CPFE IPF patients and CPFE patients with emphysema below or above 10% in the derivation and replication cohorts.

Cohort	Variable	Non-CPFE IPF patients	CPFE patients with emphysema < 10%	CPFE patients with emphysema ≥ 10%	P-value
Derivation cohort	Subjects (%)	183 (36.6)	174 (34.8)	143 (28.6)	-
	Age (years)	67.8±9.2	66.9±9.1	65.0±9.1	0.06
	Male (%)	110/183 (60.1)	143/174 (82.2)	132/143 (92.3)	0.01
	Never-/ever-smokers (ever %)	92/91 (49.7)	38/133 (77.8) *	8/134 (94.4) **	< 0.0001
	Visual fibrosis extent (%)	38.7±14.6	36.3±14.1	40.8±13.5	0.004
	Visual emphysema extent (%)	0±0	4.76±2.3	20.4±8.8	< 0.0001
	FVC (% predicted, n)	77.1±20.8 (158)	80.1±20.2 (150)	79.1±21.9 (122)	0.68
	DLco (% predicted, n)	52.2±16.5 (151)	51.6±15.1 (138)	40.4±13.3 (116)	< 0.0001
Replication cohort	Subjects (%)	152 (29.8)	206 (40.4)	152 (29.8)	-
	Age (years)	71.6±8.4	71.9±8.3	70.5±8.0	0.12
	Male (%)	96/152 (63.2)	168/206 (81.6)	128/152 (84.2)	0.60
	Never-/ever-smokers (ever %)	78/74 (48.7)	51/152 (74.9) †	22/129 (85.4) ††	0.02
	Visual fibrosis extent (%)	34.0±14.9	34.6±12.8	37.8±12.4	0.02
	Visual emphysema extent (%)	0±0	4.9±2.4	21.1±11.1	< 0.0001
	FVC (% predicted, n)	84.5±21.1 (137)	84.4±20.5 (184)	86.6±18.9 (137)	0.32
	DLco (% predicted, n)	55.2±15.1 (121)	51.2±16.0 (176)	40.7±11.2 (126)	< 0.0001
		1	1	l .	

FVC: forced vital capacity; DLco: diffusing capacity for carbon monoxide; * 171 patients and ** 142 patients had smoking data available in derivation cohort; † 203 patients and †† 151 patients had smoking data available in replication cohort; P-value shows the significance of the difference between CPFE patients with emphysema above or below 10%.

Table 2. FVC decline analysis in different subgroups of IPF patients

Cohort	Subgroup	FVC data available cases/all case	Relative 1-year FVC decline (%)	Absolute 1- year FVC decline (mls/year)
			Number of >10% Number of >5% (proportion) (proportion)	Mean
	Non-CPFE	150/183	51 (34%) 81 (54%)	163.50
Derivation cohort	CPFE with emphysema <10%	136/174	39 (28.68%) 69 (50.74%)	180.12
Conort	CPFE with emphysema ≥10%	115/143	27 (23.48%) 49 (42.61%)	97.43
	Non-CPFE	124/152	24 (19.35%) 50 (40.32%)	110.65
Replication cohort	CPFE with emphysema <10%	170/206	37 (21.76%) 75 (44.12%)	132.62
	CPFE with emphysema ≥10%	130/152	21 (16.15%) 44 (33.85%)	87.71
Combined drug trial cohort	Non-CPFE	222/236	59 (26.58%) 105 (47.30%)	142.94
	CPFE with emphysema <10%	240/261	57 (23.75%) 113 (47.08%)	164.81
	CPFE with emphysema ≥10%	150/157	29 (19.33%) 56 (37.33%)	112.19

The proportions of patients with more than 10% and 5% relative 1-year FVC decline, and the mean of absolute 1-year FVC decline in derivation, replication cohorts and combined drug trial cohort (patients fulfilling criteria to enter IPF therapeutic trials in derivation and replication cohorts) are shown in this table. The number of subjects with available FVC decline versus the number of all subjects belonging to a certain subgroup is shown in n/n format. We also compared a) non-CPFE with CPFE with emphysema $\geq 10\%$, b) CPFE with emphysema $\geq 10\%$ and CPFE with emphysema $\leq 10\%$, in terms of the relative decline and absolute decline. None of the results were statistically significantly different. CPFE: combined pulmonary fibrosis and emphysema; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity.

Table 3. DLco decline analysis in different subgroups of IPF patients

Cohort	Subgroup	DLco data available cases/all case	Relative 1-year DLo	Absolute 1- year DLco decline (mls/year)	
			Number of >15% (proportion)	Number of >10% (proportion)	Mean
-	Non-CPFE	132/183	52 (39.39%)	73 (55.30%)	645.39
Derivation cohort	CPFE with emphysema <10%	125/174	42 (33.60%)	60 (48%)	1020.97
Conort	CPFE with emphysema ≥10%	107/143	42 (39.25%)	59 (55.14%)	870.88
	Non-CPFE	108/152	30 (27.78%)	43 (39.81%)	769.10
Replication cohort	CPFE with emphysema <10%	161/206	38 (23.60%)	67 (41.61%)	615.04
	CPFE with emphysema ≥10%	117/152	42 (35.90%)	64 (54.70%)	581.21
Combined drug trial cohort	Non-CPFE	213/236	71 (33.33%)	100 (46.95%)	748.91
	CPFE with emphysema <10%	238/261	66 (27.73%)	112 (47.06%)	863.75
	CPFE with emphysema ≥10%	146/157	54 (36.99%)	80 (54.79%)	814.72

The proportions of patients with more than 15% and 10% relative 1-year DLco decline, and the mean of absolute 1-year DLco decline in derivation, replication cohorts and combined drug trial cohort (patients fulfilling criteria to enter IPF therapeutic trials in derivation and replication cohorts) are shown in this table. The number of subjects with available DLco decline versus the number of all subjects belonging to a certain subgroup is shown in n/n format. We also compared a) non-CPFE with CPFE with emphysema $\geq 10\%$, b) CPFE with emphysema $\geq 10\%$ and CPFE with emphysema <10%, in terms of the relative decline and absolute decline. None of the results were statistically significantly different. CPFE: combined pulmonary fibrosis and emphysema; IPF: idiopathic pulmonary fibrosis; DLco: diffusion capacity for carbon monoxide.

Table 4. Multivariable mixed-effects Cox proportional hazards regression models in non-CPFE patients and the two CPFE subgroups in the derivation IPF cohorts.

	Baseline severity and PFTs changes models	Entire study population					
Subgroup		N (N-observed)	C-index		Hazard	0.50/ 63	
				P-value	ratio	Lower	Upper
	DLco % predicted	130 (61)	0.821	1.94×10 ⁻⁶	0.942	0.919	0.966
	1-year FVC relative decline			3.02×10^{-8}	1.082	1.052	1.113
	DLco % predicted	120 ((1)	0.805	7.65×10 ⁻⁸	0.935	0.912	0.958
	Binary 1-year FVC decline (5%)	130 (61)		1.09×10^{-5}	3.824	2.104	6.953
N	DLco % predicted	120 ((1)	0.811	4.33×10 ⁻⁶	0.945	0.923	0.968
Non- CPFE IPF	Binary 1-year FVC decline (10%)	130 (61)		4.96×10^{-7}	4.261	2.422	7.497
patients	DLco % predicted	120 ((1)	0.002	1.62×10 ⁻⁷	0.937	0.914	0.960
patients	1-year DLco relative decline	130 (61)	0.803	0.0001	1.038	1.018	1.058
	DLco % predicted	130 (61)	0.800	4.03×10 ⁻⁷	0.940	0.918	0.963
	Binary 1-year DLco decline (10%)	130 (01)	0.800	0.0010	2.764	1.511	5.055
	DLco % predicted	130 (61)	0.811	9.11×10^{-8}	0.936	0.913	0.959
	Binary 1-year DLco decline (15%)	130 (61) 0.	0.011	4.69×10 ⁻⁷	4.211	2.407	7.366
	DLco % predicted	119 (63)	0.716	6.88×10^{-6}	0.953	0.933	0.973
	1-year FVC relative decline	119 (03)	0.710	6.46×10^{-5}	1.051	1.026	1.077
	DLco % predicted	119 (63)	0.721	1.21×10 ⁻⁵	0.956	0.937	0.976
CPFE	Binary 1-year FVC decline (5%)			0.0001	3.000	1.705	5.279
patients	DLco % predicted	119 (63)	0.685	0.0001	0.961	0.942	0.981
with	Binary 1-year FVC decline (10%)			0.025	1.983	1.091	3.604
emphyse	DLco % predicted	119 (63)	0.727	2.04×10^{-6}	0.948	0.927	0.969
ma < 10%	1-year DLco relative decline			0.0003	1.035	1.016	1.055
	DLco % predicted	119 (63)	0.682	3.38×10^{-5}	0.957	0.938	0.977
	Binary 1-year DLco decline (10%)			0.173	1.453	0.849	2.486
	DLco % predicted	119 (63)	0.696	1.47×10 ⁻⁵	0.956	0.936	0.976
	Binary 1-year DLco decline (15%)			0.017	1.979	1.131	3.464
	DLco % predicted	103 (73)	0.714	1.34×10 ⁻⁵	0.950	0.928	0.972
	1-year FVC relative decline	()		0.008	1.034	1.009	1.061
CPFE patients with emphyse ma ≥ 10%	DLco % predicted	103 (73)	0.714	3.09×10 ⁻⁵	0.954	0.932	0.975
	Binary 1-year FVC decline (5%)	. ,	0.715	0.016	1.868	1.126	3.100
	DLco % predicted	103 (73)		7.64×10 ⁻⁵	0.956	0.934	0.977
	Binary 1-year FVC decline (10%)	103 (73)	0.732	0.002	2.540	1.421	4.539
	DLco % predicted			3.26×10 ⁻⁵	0.951	0.928	0.974
	1-year DLco relative decline	103 (73)	0.703	1.24×10 ⁻⁵	1.033	1.018	1.049
	DLco % predicted			4.95×10 ⁻⁵ 0.058	0.955	0.933	0.976
	Binary 1-year DLco decline (10%)	103 (73)	0.732		1.619	0.983	2.665
	DLco % predicted			4.09×10 ⁻⁵	0.953	0.932	0.975
	Binary 1-year DLco decline (15%)			7.61×10^{-5}	2.674	1.643	4.353

Multivariable mixed-effects Cox regression models were used to investigate associations with mortality for 1-year FVC decline and 1-year DLco decline after adjusting for patient age, gender, smoking status (never versus ever), antifibrotic use (never versus ever) and baseline disease severity estimated using DLco. Binary 1-year FVC decline uses 5% and 10% relative decline as thresholds, and binary 1-year DLco decline uses 10% and 15% relative decline as thresholds. Separate centres/countries within the derivation and replication cohorts were modelled as multilevel with random effects between centres/countries (a random intercept per centre/country). N: number of patients in mixed-effects Cox model. N-observed: number of deaths observed in N patients; C-index: concordance index; CPFE: combined pulmonary fibrosis and emphysema; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; DLco: diffusing capacity for carbon monoxide; CI: confidence interval.

Table 5. Multivariable mixed-effects Cox proportional hazards regression models in non-CPFE patients and the two CPFE subgroups in the replication IPF cohorts.

	Baseline severity and PFTs changes models	Entire study population					
Subgroup		N (N-observed)	C-index	P-value	Hazar	95% CI	
					d ratio	Lower	Upper
	DLco % predicted	108 (45)	0.823	2.51×10 ⁻⁵	0.940	0.913	0.967
	1-year FVC relative decline	108 (43)		8.65×10 ⁻⁵	1.086	1.042	1.132
	DLco % predicted	108 (45)	0.827	3.35×10^{-5}	0.942	0.916	0.969
	Binary 1-year FVC decline (5%)	100 (43)		0.002	2.719	1.425	5.187
	DLco % predicted	108 (45)	0.817	5.17×10 ⁻⁵	0.944	0.918	0.971
Non-CPFE	Binary 1-year FVC decline (10%)	100 (43)		0.004	2.733	1.374	5.437
IPF patients	DLco % predicted	108 (45)	0.822	3.28×10^{-6}	0.933	0.906	0.960
	1-year DLco relative decline	100 (43)	0.022	0.019	1.032	1.005	1.059
	DLco % predicted	108 (45)	0.835	1.56×10^{-5}	0.938	0.911	0.966
	Binary 1-year DLco decline (10%)	100 (43)	0.655	0.013	2.373	1.201	4.688
	DLco % predicted	108 (45)	0.835	2.69×10^{-5}	0.941	0.915	0.968
	Binary 1-year DLco decline (15%)	100 (13)	0.055	0.006	2.693	1.336	5.428
	DLco % predicted	159 (83)	0.754	1.86×10^{-9}	0.942	0.924	0.961
	1-year FVC relative decline		0.754	0.001	1.055	1.022	1.089
	DLco % predicted	159 (83)	0.763	1.51×10 ⁻⁹	0.942	0.924	0.960
	Binary 1-year FVC decline (5%)			0.004	1.960	1.246	3.083
CPFE patients	DLco % predicted	159 (83)	0.767	8.65×10^{-10}	0.940	0.922	0.959
with	Binary 1-year FVC decline (10%)			9.27×10 ⁻⁵	2.704	1.642	4.453
emphysema <	DLco % predicted	159 (83)	0.776	5.69×10 ⁻¹¹	0.936	0.918	0.955
10%	1-year DLco relative decline			2.87×10 ⁻⁵	1.032	1.017	1.047
	DLco % predicted	150 (92)	0.772	1.74×10 ⁻¹⁰	0.937	0.919	0.956
	Binary 1-year DLco decline (10%)	159 (83)		0.0005	2.252	1.424	3.561
	DLco % predicted	159 (83)	0.768	1.78×10 ⁻⁹	0.940	0.921	0.959
	Binary 1-year DLco decline (15%)			0.0001	2.781	1.659	4.661
	DLco % predicted	115 (70)	0.705	1.23×10 ⁻⁵	0.946	0.922	0.970
	1-year FVC relative decline			0.130	1.024	0.993	1.056
	DLco % predicted	115 (70)	0.689	3.05×10 ⁻⁵	0.950	0.927	0.973
	Binary 1-year FVC decline (5%)	115 (70)		0.707	1.105	0.656	1.863
CPFE patients with emphysema ≥ 10%	DLco % predicted	115 (70)	0.706	9.84×10 ⁻⁵	0.952	0.929	0.976
	Binary 1-year FVC decline (10%)	113 (70)		0.035	2.028	1.053	3.906
	DLco % predicted	115 (70)	0.720	7.79×10 ⁻⁶	0.945	0.922	0.969
	1-year DLco relative decline			0.001	1.030	1.012	1.049
	DLco % predicted	115 (70)	0.716	1.15×10 ⁻⁵	0.948	0.925	0.971
	Binary 1-year DLco decline (10%)			0.0004	2.672	1.546	4.617
	DLco % predicted	115 (70)	0.729	1.52×10 ⁻⁵	0.948	0.925	0.971
	Binary 1-year DLco decline (15%)	115 (70)		1.04×10^{-5}	3.883	2.124	7.097
	Dinary 1-year DLCO decline (1570)	L		1.07×10	5.005	4.14	1.071

Multivariable mixed-effects Cox regression models were used to investigate associations with mortality for 1-year FVC decline and 1-year DLco decline after adjusting for patient age, gender, smoking status (never versus ever), antifibrotic use (never versus ever) and baseline disease severity estimated using DLco. Binary 1-year FVC decline uses 5% and 10% relative decline as thresholds, and binary 1-year DLco decline uses 10% and 15% relative decline as thresholds. Separate centres/countries within the derivation and replication cohorts were modelled as multilevel with random effects between centres/countries (a random intercept per centre/country). N: number of patients in mixed-effects Cox model. N-observed: number of deaths observed in N patients; C-index: concordance index; CPFE: combined pulmonary fibrosis and emphysema; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; DLco: diffusing capacity for carbon monoxide; CI: confidence interval.

References

- 1. King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. *Lancet Respir Med* 2017; 5: 72–84.
- 2. Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. *J Thorac Dis* 2015; 7: 767–779.
- 3. Cottin V, Nunes H, Brillet P, *et al.* Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. *Eur Respir J* 2005; 26: 586–593.
- 4. Cottin V, Hansell DM, Sverzellati N, et al. Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2017; 196: 1162–1171.
- 5. Cottin V, Selman M, Inoue Y, *et al.* Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. *Am J Respir Crit Care Med* 2022; 206: e7–e41.
- 6. Young AL, Marinescu R V., Oxtoby NP, *et al.* Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun* 2018; 9: 4273.
- 7. Young AL, Bragman FJS, Rangelov B, *et al.* Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2020; 201: 294–302.
- 8. Schmidt SL, Nambiar AM, Tayob N, *et al.* Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. *Eur Respir J* 2011; 38: 176–183.
- 9. Jacob J, Bartholmai BJ, Rajagopalan S, *et al.* Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. *Am J Respir Crit Care Med* 2018; 198: 767–776.
- 10. Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression. *Am J Epidemiol* 2007; 165: 710–718.
- 11. Molina Molina M, Hart E, Lesher B, *et al.* Association between FVC and mortality or survival in idiopathic pulmonary fibrosis: a systematic literature review. *Eur Respir J* 2021; 58: PA3753.
- 12. Salisbury ML, Xia M, Zhou Y, *et al.* Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. *Chest* 2016; 149: 491–498.
- 13. Doubková M, Švancara J, Svoboda M, *et al.* EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. *Clin Respir J* 2018; 12: 1526–1535.
- 14. du Bois RM, Weycker D, Albera C, et al. Ascertainment of Individual Risk of

- Mortality for Patients with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2011; 184: 459–466.
- 15. du Bois RM, Albera C, Bradford WZ, *et al.* 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. *Eur Respir J* 2014; 43: 1421 LP 1429.
- 16. Reichmann WM, Yu YF, Macaulay D, *et al.* Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. *BMC Pulm Med* 2015; 15: 167.
- 17. Bodlet A, Maury G, Jamart J, *et al.* Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis. *Respir Med* 2013; 107: 1781–1788.
- 18. Taylor Gonzalez A, Maher T. Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort. *Eur Respir J* 2016; 48: OA282.
- 19. Zurkova M, Kriegova E, Kolek V, *et al.* Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. *Respir Res* 2019; 20: 16.
- 20. Raghu G, Remy-Jardin M, Richeldi L, *et al.* Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2022; 205: e18–e47.
- 21. Akagi T, Matsumoto T, Harada T, *et al.* Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. *Respir Med* 2009; 103: 1209–1215.
- 22. Mejía M, Carrillo G, Rojas-Serrano J, *et al.* Idiopathic Pulmonary Fibrosis and Emphysema: Decreased Survival Associated With Severe Pulmonary Arterial Hypertension. *Chest* 2009; 136: 10–15.
- 23. Cottin V, Le Pavec J, Prévot G, *et al.* Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. *Eur Respir J* 2010; 35: 105 LP 111.
- 24. Walsh SLFF, Calandriello L, Silva M, *et al.* Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study. *Lancet Respir Med* 2018; 6: 837–845.
- 25. Salisbury ML, Hewlett JC, Ding G, *et al.* Development and Progression of Radiologic Abnormalities in Individuals at Risk for Familial Interstitial Lung Disease. *Am J Respir Crit Care Med* 2020; 201: 1230–1239.
- 26. Jacob J, Odink A, Brun AL, *et al.* Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. *Respir Med* 2018; 138: 95–101.




Figure 1. Computed tomography images of three subjects with 10% emphysema scored visually. A male 5-pack-year ex-smoker (age range: 56-60 years old) with axial (a) and coronal (b) imaging shows extensive upper lobe paraseptal emphysema (black arrows) and also centrilobular emphysema (white arrows) in a predominantly upper lobe distribution. Fibrosis with traction bronchiectasis, ground glass opacification and reticulation is seen in a lower zone predominant distribution. Figure c+d show respectively axial and coronal images of mixed paraseptal (black arrows) and centrilobular emphysema (white arrows) in a male 17-pack-year ex-smoker (age range: 56-60 years old). Axial images in a male

20-pack-year ex-smoker (age range: 71-75 years old) demonstrates a predominantly paraseptal distribution of emphysema (black arrows) in the upper (e) and lower (f) lobes with minimal centrilobular emphysema (white arrow).

Figure 2. Kaplan-Meier curves of non-CPFE IPF patients (red), CPFE patients with emphysema <10% (green) and CPFE patients with emphysema $\ge 10\%$ (blue) in the derivation cohort (a), the replication cohort (b), combined derivation and replication cohort patients qualifying for therapeutic trials (c). Log-rank tests show a significant difference in mortality between the three subtypes in all three analyses.